サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：プロテオミクスの世界市場：規模・シェア・動向分析 (技術別・試薬別・ソフトウェア/サービス別・用途別・エンドユーザー別)、地域別の展望、競争戦略、セグメント別の予測 (2030年まで)
市場調査レポート
商品コード
1076147

プロテオミクスの世界市場：規模・シェア・動向分析 (技術別・試薬別・ソフトウェア/サービス別・用途別・エンドユーザー別)、地域別の展望、競争戦略、セグメント別の予測 (2030年まで)

Proteomics Market Size, Share & Trends Analysis By Technology, By Reagent, By Software & Service, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 240 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
プロテオミクスの世界市場：規模・シェア・動向分析 (技術別・試薬別・ソフトウェア/サービス別・用途別・エンドユーザー別)、地域別の展望、競争戦略、セグメント別の予測 (2030年まで)
出版日: 2022年05月12日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 240 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のプロテオミクスの市場規模は今後、15.2%のCAGRで成長し、2030年までに925億5,000万米ドルに達すると予測されています。市場の主な促進要因として、感染症の流行やがん・遺伝子疾患の発症率の上昇、タンパク質・遺伝子シーケンシングの研究に対する需要拡大などが挙げられます。

当レポートでは、世界のプロテオミクスの市場について分析し、市場の基本構造や主な影響要因、全体的な市場規模の動向見通し (2019年～2030年)、技術別・試薬別・ソフトウェア/サービス別・用途別・エンドユーザー別・地域別の詳細動向、新型コロナウイルス感染症 (COVID-19) の影響、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因・抑制要因・機会・課題の分析
  • 新型コロナウイルス感染症 (COVID-19)：プロテオミクス市場への影響

第5章 市場の変動要因と展望

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 世界のプロテオミクス市場：技術別 (単位：100万米ドル、2019年～2030年)

  • 分光法
    • 質量分析
    • NMR分光法
    • CD分光法
  • クロマトグラフィー
    • HPLC
    • イオンクロマトグラフィー
    • アフィニティークロマトグラフィー
    • 超臨界流体クロマトグラフィー
  • 電気泳動
    • ゲル電気泳動
    • キャピラリー電気泳動
  • タンパク質マイクロアレイ
    • バイオチップ
    • マイクロアレイ装置
  • X線結晶構造解析
  • 表面プラズモン共鳴
  • タンパク質分画

第7章 世界のプロテオミクス市場：試薬別 (単位：100万米ドル、2019年～2030年)

  • イムノアッセイ試薬
  • 分光試薬
  • クロマトグラフィー試薬
  • タンパク質マイクロアレイ試薬
  • X線結晶構造解析試薬
  • 電気泳動試薬
  • タンパク質分画試薬

第8章 世界のプロテオミクス市場：ソフトウェア/サービス別 (単位：100万米ドル、2019年～2030年)

  • コアプロテオミクスサービス
    • タンパク質同定サービス
    • タンパク質特性評価サービス
    • 定量的プロテオミクスサービス
    • タンパク質精製サービス
    • タンパク質シーケンシングサービス
    • カスタムアッセイサービス
  • バイオインフォマティクスソフトウェア・サービス
    • バイオインフォマティクスソフトウェア
    • バイオインフォマティクスツール
    • バイオインフォマティクスデータベース

第9章 世界のプロテオミクス市場：用途別 (単位：100万米ドル、2019年～2030年)

  • 臨床診断
    • がん
    • 感染症
    • 糖尿病
    • 神経障害
    • 免疫疾患
    • 心血管疾患
    • その他の臨床診断用途
  • 創薬
    • 標的発見
    • リード識別
    • リード最適化
    • 前臨床試験
  • その他の用途

第10章 世界のプロテオミクス市場：エンドユーザー別 (単位：100万米ドル、2019年～2030年)

  • 病院
  • 臨床研究所
  • 製薬企業
  • 学術調査
  • その他のエンドユーザー

第11章 世界のプロテオミクス市場：地域別 (単位：100万米ドル、2019年～2030年)

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他中東

第12章 企業プロファイル

  • Agilent Technologies、Inc.
    • 企業概要
    • 財務展望
    • 製品概要
    • 近年の動向
  • Applied Biomics, Inc.
  • Biognosys AG
  • Biomax Informatics AG
  • Bioproximity
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Creative Proteomics
  • Danaher Corporation
  • Eurofins Scientific
  • Fios Genomics Ltd.
  • GE Healthcare
  • GENEWIZ
  • HORIBA, Ltd.
  • Illumina, Inc.
  • Integrated Proteomics Applications
  • Luminex Corporation
  • Merck KGaA
  • MRM Proteomics Inc.
  • MS Bioworks LLC
  • PerkinElmer Inc.
  • Poochon Scientific, LLC
  • Promega Corporation
  • Proteome Factory AG
  • QIAGEN Bioinformatics
目次
Product Code: BIOT2225

The global proteomics market is projected to be worth USD 92.55 billion by 2030

According to SPER Market Research, the proteomics market is estimated to reach USD 92.55 billion by 2030 with a CAGR of 15.2%. The rising prevalence of infectious diseases has increased the demand for the study of proteins and gene sequencing. This study can help in developing novel treatments against viral diseases, cancer, and other genetic disorders.

Impact of COVID-19 on the proteomics Market

The COVID-19 pandemic has increased the focus on decoding 3d structures of SARS-CoV-2 proteins. In order to understand therapies against COVID-19, protein crystallization techniques have played a significant role to understand virus proteins and specific sites. This has impacted the proteomics market in positively and the marker has grown further.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Technology, By Reagents, By Software & Services, By Application, By End-User.

Geographies covered: North America, Europe, APAC, Latin America and the Middle East & Africa.

Companies Covered:

Agilent Technologies, Inc., Applied Biomics, Inc., Biognosys AG, Biomax Informatics AG, Bioproximity, Bio-Rad Laboratories, Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, Eurofins Scientific, Fios Genomics Ltd., GE Healthcare, GENEWIZ, HORIBA, Ltd., Illumina, Inc., Integrated Proteomics Applications, Luminex Corporation, Merck KGaA, MRM Proteomics Inc., MS Bioworks LLC, PerkinElmer Inc., Poochon Scientific, LLC, Promega Corporation, Proteome Factory AG, QIAGEN Bioinformatics

Driver: Rising incidence of cancer and genetic disorders

The incidence of cancer and geriatric disorders is rising creating an urgent need for better therapeutics. The recent discoveries around the sequencing of the human genome are helping in developing novel treatments by evaluating gene expression at the proteome level. The extraction of biological information in diseased patients can help in the development of novel treatments and thus can drive the proteomics market

Opportunity: Rising demand for nanoproteomics

Nanotechnology is gaining popularity in the plethora of applications in various industries. In proteomics, nanotechnology can be utilized to develop phosphoproteomics, nanostructured surfaces for protein separation, and detection techniques for biomarkers protein. The growth of nanoproteomics technology is providing growth opportunities to the proteomics market

Challenge: High cost of equipment

The research activities involved in proteomics & genomics involve highly expensive instruments and reagents. The cost of installation along with maintenance charges and indirect costs makes it very challenging for developing countries to adopt these technologies

Proteomics Market by Technology:

Based on technology, the market has been segmented into Spectroscopy (Mass Spectroscopy, NMR Spectroscopy, CD Spectroscopy), Chromatography (HPLC, Ion Chromatography, Affinity Chromatography, Supercritical Fluid Chromatography), Electrophoresis (Gel Electrophoresis, Capillary Electrophoresis), Protein Microarrays (Biochips [Lab-on-Chips, Protein Chips], Micrparray Instruments [Integrated Systems, Microarray Scanners, Arrayers]), X-Ray Crystallography, Surface Plasmon Resonance, Protein Fractionation

Proteomics Market by Reagents:

Based on reagents, the market is segmented into Immunoassay Reagents, Spectroscopy Reagents, Chromatography Reagents, Protein Microarray Reagents, X-Ray Crystallography Reagents, Electrophoresis Reagents, Protein Fractionation Reagents

Proteomics Market by Software & Services:

Based on software & services, the market is segmented into Core Proteomics Services (Protein Identification Services, Protein Characterization Services, Quantitative Proteomic Services, Protein Purification Services, Protein Sequencing Services, Custom Assay Services), Bioinformatics Software & Services (Bioinformatics Software, Bioinformatics Tools, Bioinformatics Databases)

Proteomics Market by Application:

Based on application, the market is segmented into Clinical Diagnostics (Cancer, Infectious Diseases, Diabetes, Neurological Disorders, Immune Diseases, Cardiovascular Diseases, and Other Clinical Diagnostic Applications), Drug Discovery (Target Discovery, Lead Identification, Lead Optimization, Preclinical Studies), Other Application

Proteomics Market by End User:

Based on end-users, the market is segmented into Hospitals, Clinical Laboratories, Pharmaceutical Companies, Academic Research Laboratories, and Other End Users.

Pharmaceutical & Biotechnological companies have the largest share of this market by the end-user due to rising public & private funding for proteomics & genomics research activities and rising outsourcing of research activities to CRO services associated with pharmaceutical companies

Proteomics Market by Region:

North America owns the largest share of this market owing to rising investments & funding, rising preference for high-quality research, focus on reproducibility in research, raising awareness for personalized medicines, and presence of leading players in this market

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary data
    • 2.1.2. Primary data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impact on the Proteomics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL analysis
    • 5.2.1. Political landscape
    • 5.2.2. Economic landscape
    • 5.2.3. Social landscape
    • 5.2.4. Technological landscape
    • 5.2.5. Environmental landscape
    • 5.2.6. Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of Buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat map analysis

6. Global Proteomics Market, By Technology, 2019-2030 (USD Million)

  • 6.1. Spectroscopy
    • 6.1.1. Mass Spectroscopy
    • 6.1.2. NMR Spectroscopy
    • 6.1.3. CD Spectroscopy
  • 6.2. Chromatography
    • 6.2.1. HPLC
    • 6.2.2. Ion Chromatography
    • 6.2.3. Affinity Chromatography
    • 6.2.4. Supercritical Fluid Chromatography
  • 6.3. Electrophoresis
    • 6.3.1. Gel Electrophoresis
    • 6.3.2. Capillary Electrophoresis
  • 6.4. Protein Microarrays
    • 6.4.1. Biochips
      • 6.4.1.1. Lab-on-Chips
      • 6.4.1.2. Protein Chips
    • 6.4.2. Micrparray Instruments
      • 6.4.2.1. Integrated Systems
      • 6.4.2.2. Microarray Scanners
      • 6.4.2.3. Arrayers
  • 6.5. X-Ray Crystallography
  • 6.6. Surface Plasmon Resonance
  • 6.7. Protein Fractionation

7. Global Proteomics Market, By Reagents, 2019-2030 (USD Million)

  • 7.1. Immunoassay Reagents
  • 7.2. Spectroscopy Reagents
  • 7.3. Chromatography Reagents
  • 7.4. Protein Microarray Reagents
  • 7.5. X-Ray Crystallography Reagents
  • 7.6. Electrophoresis Reagents
  • 7.7. Protein Fractionation Reagents

8. Global Proteomics Market, By Software & Services, 2019-2030 (USD Million)

  • 8.1. Core Proteomics Services
    • 8.1.1. Protein Identification Services
    • 8.1.2. Protein Characterization Services
    • 8.1.3. Quantitative Proteomic Services
    • 8.1.4. Protein Purification Services
    • 8.1.5. Protein Sequencing Services
    • 8.1.6. Custom Assay Services
  • 8.2. Bioinformatics Software & Services
    • 8.2.1. Bioinformatics Software
    • 8.2.2. Bioinformatics Tools
    • 8.2.3. Bioinformatics Databases

9. Global Proteomics Market, By Application, 2019-2030 (USD Million)

  • 9.1. Clinical Diagnostics
    • 9.1.1. Cancer
    • 9.1.2. Infectious Diseases
    • 9.1.3. Diabetes
    • 9.1.4. Neurological Disorders
    • 9.1.5. Immune Diseases
    • 9.1.6. Cardiovascular Diseases
    • 9.1.7. Other Clinical Diagnostic Applications
  • 9.2. Drug Discovery
    • 9.2.1. Target Discovery
    • 9.2.2. Lead Identification
    • 9.2.3. Lead Optimization
    • 9.2.4. Preclinical Studies
  • 9.3. Other Application

10. Global Proteomics Market, By End User, 2019-2030 (USD Million)

  • 10.1. Hospitals
  • 10.2. Clinical Laboratories
  • 10.3. Pharmaceutical Companies
  • 10.4. Academic Research Laboratories
  • 10.5. Other End Users

11. Global Proteomics Market, By Region, 2019-2030 (USD Million)

  • 11.1. North America
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Mexico
  • 11.2. Europe
    • 11.2.1. Germany
    • 11.2.2. United Kingdom
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. Asia-Pacific
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. Australia
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. South America
    • 11.4.1. Brazil
    • 11.4.2. Argentina
    • 11.4.3. Rest of South America
  • 11.5. Middle East & Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Rest of Middle East & Africa

12. Company Profiles

  • 12.1. Agilent Technologies, Inc.
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Applied Biomics, Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. Biognosys AG
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Biomax Informatics AG
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. Bioproximity
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Bio-Rad Laboratories, Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. Bruker Corporation
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Creative Proteomics
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Danaher Corporation
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Eurofins Scientific
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Fios Genomics Ltd.
    • 12.11.1. Company details
    • 12.11.2. Financial outlook
    • 12.11.3. Product summary
    • 12.11.4. Recent developments
  • 12.12. GE Healthcare
    • 12.12.1. Company details
    • 12.12.2. Financial outlook
    • 12.12.3. Product summary
    • 12.12.4. Recent developments
  • 12.13. GENEWIZ
    • 12.13.1. Company details
    • 12.13.2. Financial outlook
    • 12.13.3. Product summary
    • 12.13.4. Recent developments
  • 12.14. HORIBA, Ltd.
    • 12.14.1. Company details
    • 12.14.2. Financial outlook
    • 12.14.3. Product summary
    • 12.14.4. Recent developments
  • 12.15. Illumina, Inc.
    • 12.15.1. Company details
    • 12.15.2. Financial outlook
    • 12.15.3. Product summary
    • 12.15.4. Recent developments
  • 12.16. Integrated Proteomics Applications
    • 12.16.1. Company details
    • 12.16.2. Financial outlook
    • 12.16.3. Product summary
    • 12.16.4. Recent developments
  • 12.17. Luminex Corporation
    • 12.17.1. Company details
    • 12.17.2. Financial outlook
    • 12.17.3. Product summary
    • 12.17.4. Recent developments
  • 12.18. Merck KGaA
    • 12.18.1. Company details
    • 12.18.2. Financial outlook
    • 12.18.3. Product summary
    • 12.18.4. Recent developments
  • 12.19. MRM Proteomics Inc.
    • 12.19.1. Company details
    • 12.19.2. Financial outlook
    • 12.19.3. Product summary
    • 12.19.4. Recent developments
  • 12.20. MS Bioworks LLC
    • 12.20.1. Company details
    • 12.20.2. Financial outlook
    • 12.20.3. Product summary
    • 12.20.4. Recent developments
  • 12.21. PerkinElmer Inc.
    • 12.21.1. Company details
    • 12.21.2. Financial outlook
    • 12.21.3. Product summary
    • 12.21.4. Recent developments
  • 12.22. Poochon Scientific, LLC
    • 12.22.1. Company details
    • 12.22.2. Financial outlook
    • 12.22.3. Product summary
    • 12.22.4. Recent developments
  • 12.23. Promega Corporation
    • 12.23.1. Company details
    • 12.23.2. Financial outlook
    • 12.23.3. Product summary
    • 12.23.4. Recent developments
  • 12.24. Proteome Factory AG
    • 12.24.1. Company details
    • 12.24.2. Financial outlook
    • 12.24.3. Product summary
    • 12.24.4. Recent developments
  • 12.25. QIAGEN Bioinformatics
    • 12.25.1. Company details
    • 12.25.2. Financial outlook
    • 12.25.3. Product summary
    • 12.25.4. Recent developments